Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Bortezomib to treat the TEMPI syndrome.

Kwok M, Korde N, Landgren O.

N Engl J Med. 2012 May 10;366(19):1843-5. doi: 10.1056/NEJMc1202649. No abstract available.

2.

Complete and partial responses of the TEMPI syndrome to bortezomib.

Schroyens W, O'Connell C, Sykes DB.

N Engl J Med. 2012 Aug 23;367(8):778-80. doi: 10.1056/NEJMc1205806. No abstract available.

3.

The TEMPI syndrome--a novel multisystem disease.

Sykes DB, Schroyens W, O'Connell C.

N Engl J Med. 2011 Aug 4;365(5):475-7. doi: 10.1056/NEJMc1106670. No abstract available.

4.

Subcutaneous bortezomib for treatment of TEMPI syndrome.

Jasim S, Mahmud G, Bastani B, Fesler M.

Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):e221-3. doi: 10.1016/j.clml.2014.07.004. No abstract available.

PMID:
25172534
5.

Treatment of light chain deposition disease with bortezomib and dexamethasone.

Kastritis E, Migkou M, Gavriatopoulou M, Zirogiannis P, Hadjikonstantinou V, Dimopoulos MA.

Haematologica. 2009 Feb;94(2):300-2. doi: 10.3324/haematol.13548. No abstract available.

6.

[Bortezomib-based therapy in patients with light chain deposition disease].

Minařík J, Tichý T, Pika T, Bačovský J, Adamová D, Srovnalík K, Krejčí K, Zadražil J, Sčudla V.

Vnitr Lek. 2014 Oct;60(10):821-6. Czech.

PMID:
25382003
7.

Bortezomib therapy in myelofibrosis: a phase II clinical trial.

Mesa RA, Verstovsek S, Rivera C, Pardanani A, Hussein K, Lasho T, Wu W, Tefferi A.

Leukemia. 2008 Aug;22(8):1636-8. doi: 10.1038/leu.2008.32. No abstract available.

PMID:
18305559
8.

Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma.

Fröhlich K, Holle JU, Aries PM, Gross WL, Moosig F.

Ann Rheum Dis. 2011 Jul;70(7):1344-5. doi: 10.1136/ard.2010.133256. No abstract available.

PMID:
21173019
9.

Concurrent radiation therapy and bortezomib in myeloma patient.

Berges O, Decaudin D, Servois V, Kirova YM.

Radiother Oncol. 2008 Feb;86(2):290-2. doi: 10.1016/j.radonc.2007.12.015. No abstract available.

PMID:
18199515
10.

Refractory atypical hemolytic uremic syndrome with monoclonal gammopathy responsive to bortezomib-based therapy.

Cheungpasitporn W, Leung N, Sethi S, Gertz MA, Fervenza FC.

Clin Nephrol. 2015 Jun;83(6):363-9. doi: 10.5414/CN108363.

PMID:
25345382
11.

Bortezomib therapy following first relapse.

Orlowski RZ; Multiple Myeloma Research Foundation..

Oncology (Williston Park). 2005 Jan;19(1):23-6. No abstract available.

PMID:
15743149
12.

Efficacy of Bortezomib followed by local irradiation in two patients with extramedullary plasmacytomas.

Varettoni M, Mangiacavalli S, Zappasodi P, Pica GM, Lazzarino M, Corso A.

Leuk Res. 2008 May;32(5):839-41. No abstract available.

PMID:
17997154
13.

Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma.

Younes A, Pro B, Fayad L.

Blood. 2006 Feb 15;107(4):1731-2. No abstract available.

14.

[Bortezomib (Velcade). Laboratory: Millenium Pharmaceuticals Inc].

Moreno Alvarez PJ.

Farm Hosp. 2003 Jul-Aug;27(4):274-5. Spanish. No abstract available.

PMID:
12966459
15.

Bortezomib-induced Sweet syndrome.

Knoops L, Jacquemain A, Tennstedt D, Theate I, Ferrant A, Van den Neste E.

Br J Haematol. 2005 Oct;131(2):142. No abstract available.

PMID:
16197442
16.

Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.

Mele G, Pinna S, Alloro E, Brocca MC, Coppi MR, Quarta G.

Leuk Res. 2007 May;31(5):721-3. No abstract available.

PMID:
16890285
17.

Use of intrapleural bortezomib in myelomatous pleural effusion.

Iannitto E, Minardi V, Tripodo C.

Br J Haematol. 2007 Nov;139(4):621-2. No abstract available.

PMID:
17979947
18.

Still no certainty about the role of upfront bortezomib among patients with AL amyloidosis.

Dispenzieri A.

Leukemia. 2014 Dec;28(12):2273-5. doi: 10.1038/leu.2014.271. No abstract available.

PMID:
25492370
19.

Generalized cutis laxa and fibrillar glomerulopathy resulting from IgG Deposition in IgG-lambda Monoclonal Gammopathy: pulmonary hemorrhage during stem cell mobilization and complete hematological response with bortezomib and dexamethasone therapy.

Fernández de Larrea C, Rovira M, Mascaró JM Jr, Torras A, Solé M, Lloreta J, Serra N, Cibeira MT, Bladé J.

Eur J Haematol. 2009 Feb;82(2):154-8. doi: 10.1111/j.1600-0609.2008.01181.x.

PMID:
19018863
20.

Bortezomib and extramedullary disease in multiple myeloma: the shine and dark side of the moon.

Ali R, Ozkalemkas F, Ozkan A, Ozkocaman V, Ozcelik T, Ozan U, Kurt M, Tunali A.

Leuk Res. 2007 Aug;31(8):1153-5. No abstract available.

PMID:
16945413

Supplemental Content

Support Center